Trial
NCT01600053
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Thomas Kipps
Collaborators
Celgene Corporation
Condition
Chronic Lymphocytic Leukemia
Intervention
Lenalidomide
Why stopped
interim analysis showed that the trial will not meet the interim endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-15